Skip to main content

Table 1 Study profile and characteristics of patients enrolled in Felegeselam and Arbaminch Health Centers, Ethiopia, 2017

From: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia

 

P. falciparum

P. vivax

AL

n = 106

DHA/PPQ

n = 75

CQ

n = 142

DHA/PPQ

n = 56

Median age, years (range)

15 (1–57)

25 (18–65)

14 (1–70)

23 (18–70)

Age groups, years (n)

    

 6 months̵̵̵– ≤ 5 years

2

n/a

17

n/a

  > 5– < 18 years

75

n/a

82

n/a

  ≥ 18 years

29

75

43

56

Median weight, kg (range)

45 (8–79)

53 (39–71)

42 (9–78)

59 (41–106)

Percent male, %

66.0

70.7

56.3

64.3

Median day 0 parasitaemia, parasites/µl (range)

18,255

(520–97,326)

8755

(524–96,000)

10,051

(520–48,320)

5373

(737–30,320)

Median day 0 gametocyte density, gametocytes/µl (range)

0

0

(0–3520)

401

(0–14,023)

320

(0–10,000)

Median day 0 haemoglobin, g/dl (range)

13.3 (8.6–18.7)

13.3 (7.4–17.6)

12.8 (7.3–18.3)

14.3 (9.9–17.6)

  1. P Plasmodium, AL artemether-lumefantrine, DHA/PPQ Dihydroartemisinin-piperaquine, CQ Chloroquine